Drugs / OSCN-
last change Dec 2021 re-read 3 minutes ago

OSCN-

Developed for
bronchiectasis · cystic fibrosis
Investigated by
Alaxia SAS

Trials 1

201620172018201920202021202220232024202520262027
PhaseRegistry idDatesIndicationSponsorStatusOutcome
Phase 1 NCT02598999 Nov 2015 → Dec 2021 bronchiectasis, cystic fibrosis Alaxia SAS Terminated No outcome recorded Stop: Business

Evidence & citations 2 cited values

Every value below carries the sentence it was read from. 1 source stands behind the page.

FieldValueCited text
Known as OSCN- ClinicalTrials.gov intervention name — accepted as the source's own label NCT02598999 ↗
Route Inhaled “Solution for inhalation administered through nebulization” NCT02598999 ↗